Teachers Retirement System of The State of Kentucky Buys New Position in Amneal Pharmaceuticals, Inc. $AMRX

Teachers Retirement System of The State of Kentucky purchased a new position in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 40,000 shares of the company’s stock, valued at approximately $497,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Assenagon Asset Management S.A. grew its position in Amneal Pharmaceuticals by 75.0% in the fourth quarter. Assenagon Asset Management S.A. now owns 3,761,739 shares of the company’s stock valued at $47,398,000 after acquiring an additional 1,611,698 shares in the last quarter. Westshore Wealth LLC purchased a new stake in shares of Amneal Pharmaceuticals during the third quarter valued at approximately $13,833,000. Morgan Stanley lifted its position in shares of Amneal Pharmaceuticals by 37.5% during the fourth quarter. Morgan Stanley now owns 4,818,099 shares of the company’s stock worth $60,708,000 after purchasing an additional 1,315,018 shares in the last quarter. Penn Capital Management Company LLC acquired a new position in shares of Amneal Pharmaceuticals during the fourth quarter worth $12,655,000. Finally, Rubric Capital Management LP boosted its stake in shares of Amneal Pharmaceuticals by 9.1% in the second quarter. Rubric Capital Management LP now owns 11,710,332 shares of the company’s stock valued at $94,737,000 after purchasing an additional 974,355 shares during the period. Hedge funds and other institutional investors own 31.82% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on AMRX shares. Zacks Research lowered shares of Amneal Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Monday, April 6th. Weiss Ratings cut shares of Amneal Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Tuesday, May 26th. Barclays raised their target price on Amneal Pharmaceuticals from $15.00 to $16.00 and gave the company an “overweight” rating in a research note on Wednesday, May 20th. Wall Street Zen raised Amneal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Sunday, July 12th. Finally, UBS Group boosted their price target on Amneal Pharmaceuticals from $19.00 to $23.00 and gave the stock a “buy” rating in a research note on Wednesday. Five research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $16.60.

Insider Buying and Selling at Amneal Pharmaceuticals

In other news, Director Deborah M. Autor sold 34,819 shares of the business’s stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $12.94, for a total value of $450,557.86. Following the completion of the sale, the director owned 93,660 shares of the company’s stock, valued at approximately $1,211,960.40. The trade was a 27.10% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 17.30% of the company’s stock.

Amneal Pharmaceuticals Trading Up 4.9%

AMRX stock opened at $18.04 on Friday. Amneal Pharmaceuticals, Inc. has a twelve month low of $7.66 and a twelve month high of $18.08. The company has a market capitalization of $5.76 billion, a P/E ratio of 47.47 and a beta of 1.26. The firm has a 50 day simple moving average of $14.95 and a 200-day simple moving average of $13.86.

Amneal Pharmaceuticals (NASDAQ:AMRX) last posted its quarterly earnings results on Thursday, May 7th. The company reported $0.27 earnings per share (EPS) for the quarter. Amneal Pharmaceuticals had a net margin of 4.01% and a negative return on equity of 313.96%. The firm had revenue of $722.52 million for the quarter. On average, research analysts predict that Amneal Pharmaceuticals, Inc. will post 0.92 EPS for the current year.

Amneal Pharmaceuticals Profile

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.